Abivax SA (AAVXF)
15.15
0.00 (0.00%)
USD |
OTCM |
Jun 24, 16:00
Abivax Enterprise Value: 725.42M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 725.42M |
| June 24, 2024 | 725.42M |
| June 21, 2024 | 725.42M |
| June 20, 2024 | 725.42M |
| June 18, 2024 | 725.42M |
| June 17, 2024 | 725.42M |
| June 14, 2024 | 725.42M |
| June 13, 2024 | 725.42M |
| June 12, 2024 | 725.42M |
| June 11, 2024 | 725.42M |
| June 10, 2024 | 725.42M |
| June 07, 2024 | 725.42M |
| June 06, 2024 | 725.42M |
| June 05, 2024 | 725.42M |
| June 04, 2024 | 725.42M |
| June 03, 2024 | 725.42M |
| May 31, 2024 | 725.42M |
| May 30, 2024 | 725.42M |
| May 29, 2024 | 725.42M |
| May 28, 2024 | 725.42M |
| May 24, 2024 | 725.42M |
| May 23, 2024 | 725.42M |
| May 22, 2024 | 725.42M |
| May 21, 2024 | 725.42M |
| May 20, 2024 | 725.42M |
| Date | Value |
|---|---|
| May 17, 2024 | 725.42M |
| May 16, 2024 | 725.42M |
| May 15, 2024 | 725.42M |
| May 14, 2024 | 725.42M |
| May 13, 2024 | 725.42M |
| May 10, 2024 | 725.42M |
| May 09, 2024 | 725.42M |
| May 08, 2024 | 725.42M |
| May 07, 2024 | 725.42M |
| May 06, 2024 | 725.42M |
| May 03, 2024 | 725.42M |
| May 02, 2024 | 725.42M |
| May 01, 2024 | 725.42M |
| April 30, 2024 | 725.42M |
| April 29, 2024 | 725.42M |
| April 26, 2024 | 725.42M |
| April 25, 2024 | 725.42M |
| April 24, 2024 | 725.42M |
| April 23, 2024 | 725.42M |
| April 22, 2024 | 725.42M |
| April 19, 2024 | 461.16M |
| April 18, 2024 | 461.16M |
| April 17, 2024 | 461.16M |
| April 16, 2024 | 461.16M |
| April 15, 2024 | 461.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
79.44M
Minimum
Jun 28 2019
858.34M
Maximum
May 31 2023
398.37M
Average
358.20M
Median
Apr 04 2023
Enterprise Value Benchmarks
| DBV Technologies SA | -8.809M |
| Cellectis SA | 88.97M |
| Genfit SA | 175.06M |
| Innate Pharma SA | 102.08M |
| Inventiva SA | 161.17M |
Enterprise Value Related Metrics
| Earnings Yield | -23.37% |
| Normalized Earnings Yield | -20.10 |